RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Lymphoma drug trial stopped after no safe dose found
Disease control OngoingThis early-stage trial tested whether adding a new drug called tolinapant to an existing oral lymphoma treatment (decitabine/cedazuridine) was safe and effective for people with relapsed T-cell lymphoma. The study aimed to find the right dose and see if the combination could shri…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing an oral drug called valemetostat in adults whose peripheral T-cell lymphoma has come back or hasn't responded to prior treatments. The main goal is to see if the drug safely shrinks tumors and for how long. It includes 155 participants and focuses on measuri…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC